Articles published by Acorda Therapeutics
![](https://mms.businesswire.com/media/20240415205418/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Delisting from Nasdaq
April 15, 2024
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20240403709790/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Nasdaq Delisting Notification
April 03, 2024
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20240401939079/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
April 01, 2024
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20240325991670/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
March 25, 2024
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20240110989288/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
January 11, 2024
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20231113118027/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20231106959067/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
November 06, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20231106056064/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230808758177/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230802544540/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230801613678/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
August 01, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230628900808/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230626647791/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230602005209/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230531005970/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230530005166/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230511005653/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230510005117/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
May 10, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230508005309/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230504005726/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230424005261/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
April 24, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230403005358/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230327005219/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
March 27, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230309005345/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230307005326/en/1596352/5/Acorda_Logo-Color_Print.jpg)
ESTEVE Launches INBRIJA® in Spain
March 07, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230306005798/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
March 06, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230214005861/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230131006066/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics to Present at Sequire Biotechnology Conference
January 31, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20230105006013/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
January 05, 2023
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
![](https://mms.businesswire.com/media/20221222005261/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
December 22, 2022
From Acorda Therapeutics
Via Business Wire
Tickers
ACOR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.